GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Pretax Margin %

ARTH (Arch Therapeutics) Pretax Margin % : -18,241.94% (As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Arch Therapeutics's Pre-Tax Income for the three months ended in Jun. 2024 was $-5.66 Mil. Arch Therapeutics's Revenue for the three months ended in Jun. 2024 was $0.03 Mil. Therefore, Arch Therapeutics's pretax margin for the quarter that ended in Jun. 2024 was -18,241.94%.

The historical rank and industry rank for Arch Therapeutics's Pretax Margin % or its related term are showing as below:

ARTH' s Pretax Margin % Range Over the Past 10 Years
Min: -52000   Med: -32975   Max: -8230.2
Current: -8230.2


ARTH's Pretax Margin % is ranked worse than
91.41% of 1001 companies
in the Biotechnology industry
Industry Median: -136.49 vs ARTH: -8230.20

Arch Therapeutics Pretax Margin % Historical Data

The historical data trend for Arch Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics Pretax Margin % Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -52,000.00 -32,975.00 -9,188.16

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14,023.08 -6,142.50 -5,830.43 -4,590.63 -18,241.94

Competitive Comparison of Arch Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Arch Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Pretax Margin % falls into.


;
;

Arch Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Arch Therapeutics's Pretax Margin for the fiscal year that ended in Sep. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-6.983/0.076
=-9,188.16 %

Arch Therapeutics's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-5.655/0.031
=-18,241.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Therapeutics  (OTCPK:ARTH) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Arch Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Therapeutics Business Description

Traded in Other Exchanges
Address
235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Executives
Terrence W Norchi director, officer: President & CEO C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams officer: CFO and Treasurer 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen officer: Vice President, Sales C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat director
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis officer: CFO & Treasurer
Avtar S Dhillon director C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal director 100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber officer: Chief Financial Officer C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter officer: Chief Operating Officer C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616

Arch Therapeutics Headlines

From GuruFocus